Human Longevity, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • Bioinformatics
  • Research, Analytical Equipment & Supplies
  • Services
  • Pharmaceuticals
  • In Vitro Diagnostics
See more in Biomedtracker

Latest on Human Longevity, Inc.

In Vivo

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

When Ann Beliën watched her father struggle with age-related diseases that didn’t respond to conventional treatments, she faced a choice that would define her career. She could accept the pharmaceutic

Scrip

Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate

 
• By Deanna Kamienski

The amount of venture capital raised by start-ups in the first quarter more than doubled year-over-year compared with the first quarter of 2017, but acquisitions were stagnant in Q1 versus the prior q

Scrip

Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B

 
• By Deanna Kamienski, Beth Allan, and Maureen Riordan

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bioph

In Vivo

Deals Shaping The Medical Industry, February 2018

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

IN VITRO DIAGNOSTICS Financings HTG Molecular Diagnostics Inc. HTG Molecular Diagnostics Inc. netted $37.9mm through a public offering of 13.9mm common shares (including the overallotment) at $2.9